Given the prognostic heterogeneity of NPM1-mutations, we wanted to investigate the impact of PRDM16 expression in a large cohort of 503 intensively treated, well-annotated adult AML patients with NPM1 mutations. This evidence concerns the gene NPM1 and acute myeloid leukemia.